Compare NPK & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPK | GHRS |
|---|---|---|
| Founded | 1905 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 945.9M | 947.2M |
| IPO Year | 1994 | 2021 |
| Metric | NPK | GHRS |
|---|---|---|
| Price | $125.00 | $28.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $41.38 |
| AVG Volume (30 Days) | 107.8K | ★ 256.9K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | ★ 0.71% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.99 | N/A |
| Revenue | ★ $503,524,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $124.97 | ★ N/A |
| Revenue Growth | ★ 29.70 | N/A |
| 52 Week Low | $91.28 | $11.32 |
| 52 Week High | $149.86 | $25.94 |
| Indicator | NPK | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 40.26 | 73.23 |
| Support Level | $123.35 | $12.88 |
| Resistance Level | $135.46 | N/A |
| Average True Range (ATR) | 4.33 | 1.72 |
| MACD | -0.23 | 0.53 |
| Stochastic Oscillator | 19.94 | 95.38 |
National Presto Industries Inc has an electric product portfolio consisting of household appliances, ammunition, and diapers. The company operates in three segments, namely Defense, Housewares/Small Appliance, and Safety. The defense segment, which is engaged in manufacturing 40mm ammunition, precision mechanical and electro-mechanical assemblies, and medium caliber cartridge cases, performs Load, Assemble, and Pack (LAP) operations on ordnance-related products for the U.S. Government and prime contractor. While the Housewares/Small Appliance segment designs, markets, and distributes housewares and small electrical appliances, the safety segment provides safety technology empowering organizations and individuals to protect what is more important.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.